CMCS-Beijing: Chinese Multi-provincial Cohort Study-Beijing Project
Study Details
Study Description
Brief Summary
The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- All fatal and nonfatal acute coronary and stroke events [From date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 years]
Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths. Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.
Secondary Outcome Measures
- New-onset of coronary events [From date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 years]
Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths.
- New-onset of stroke [From date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 years]
Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.
- Total death [From date of enrollment until date of death from all cause, assessed at least 5 years]
All cause death
- Cognitive dysfunction [From date of enrollment until date of first documented event, assessed at least 5 years]
Cognitive dysfunction
- Olfactory Disorders [From date of enrollment until date of first documented event, assessed at least 5 years]
Olfactory Disorders
- Valvular disease [From date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 years]
Valvular disease
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants from CMCS-Beijing
-
sign the informed consent
Exclusion Criteria:
- participanting in clinical trials
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Beijing Sijiqing Hospital, Beijing | Beijing | China | ||
2 | Peking University Hospital, Beijing | Beijing | China | ||
3 | Peking University Shougang Hospital | Beijing | China |
Sponsors and Collaborators
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
Investigators
- Principal Investigator: Jing Liu, MD, PhD, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMCS-Beijing 2020